Evidence map›Paper›PMID 29064044›Full record

ReviewCurrent cardiology reports2017

Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants.

Scott Kaatz, Charles E Mahan, Asaad Nakhle, Kulothungan Gunasekaran, Mahmoud Ali, Robert Lavender, David G Paje

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. [Special situations of preconditioning and prehabilitation in oncological visceral surgery].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2018
    Review
  11. Article
  12. Protein S: a Multifunctional Anticoagulant.Biomedical research and clinical practice · 2017
    Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Scott KaatzDivision of Hospital Medicine, Henry Ford Hospital, 2799 W. Grand Blvd, Detroit, MI, 48202, USA. Skaatz1@hfhs.org.
Charles E MahanDepartment of Pharmacy, University of New Mexico, Presbyterian Healthcare Services, 1100 Central Ave. SE, Albuquerque, NM, 87106, USA.
Asaad NakhleDepartment of Internal Medicine, Henry Ford Hospital, 2799 W. Grand Blvd, Detroit, MI, 48202, USA.
Kulothungan GunasekaranDivision of Hospital Medicine, Henry Ford Hospital, 2799 W. Grand Blvd, Detroit, MI, 48202, USA.
Mahmoud AliDepartment of Internal Medicine, Henry Ford Hospital, 2799 W. Grand Blvd, Detroit, MI, 48202, USA.
Robert LavenderDivision of General Internal Medicine, University of Arkansas for Medical Sciences, 4301 W. Markham St, Little Rock, AR, USA.
David G PajeDepartment of Internal Medicine, University of Michigan Medical School, 1500 E. Medical Center Dr, Ann Arbor, MI, 48109, USA.
Henry Ford Hospital · USPresbyterian Healthcare Services · USUniversity of Arkansas for Medical Sciences · USUniversity of Michigan–Ann Arbor · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe purpose of this review was to offer practical management strategies for when patients receiving direct oral anticoagulants require elective surgery or present with bleeding complications. RECENT

findingsClinical practice guidelines are now available on the timing of periprocedural interruption of treatment with the newer direct oral anticoagulants based on their pharmacodynamics and pharmacokinetics and based on findings from cohort studies and clinical trials. An antibody that reverses the effects of dabigatran is now available, and a factor Xa decoy is being developed as an antidote to apixaban, betrixaban, edoxaban, and rivaroxaban. The timing of interruption of direct oral anticoagulants for elective surgery is based on multiple factors, including pharmacologic properties and interactions, the patient's renal function, and the type of planned surgery. There is little role for low-molecular-weight heparin bridging. Idarucizumab is the treatment of choice for dabigatran-related life-threatening bleeding, while andexanet alfa is being developed to reverse factor Xa inhibitors.

Indexed as

DeprescriptionsPractice Guidelines as TopicAdministration, OralAntibodies, Monoclonal, HumanizedAnticoagulantsAntidotesAntithrombinsBenzamidesBlood Loss, SurgicalDabigatranElective Surgical ProceduresFactor XaFactor Xa InhibitorsHemorrhageHumansPyrazolesAntibodies, Monoclonal, HumanizedAnticoagulantsAntidotesAntithrombinsapixabanBenzamidesbetrixabanDabigatranedoxabanFactor XaFactor Xa InhibitorsidarucizumabPRT064445PyrazolesPyridinesPyridonesRecombinant ProteinsRivaroxabanThiazolesAndexanet alfaBleedingDirect oral anticoagulants (DOAC)IdarucizumabReversalSurgery

Identifiers

PMID29064044
OpenAlexW2766002115

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.